Blog for Stock tips, Equity tips, Commodity tips, Forex tips: Sharetipsinfo.com

http://sharetipsinfo.comJust get registered at Sharetipsinfo and earn positive returns

Benchmark indices ended on negative note on November 16 with Nifty below 18000 dragged by the bank, pharma, oil & gas and metals stocks.

At close, the Sensex was down 396.34 points or 0.65% at 60,322.37, and the Nifty was down 110.30 points or 0.61% at 17,999.20. About 1496 shares have advanced, 1639 shares declined, and 122 shares are unchanged.

Shree Cements, Reliance Industries, Hindalco Industries, Tata Consumer Products, SBI were among the major Nifty losers. However, gainers included Maruti Suzuki, M&M, Tata Motors, Hero MotoCorp and Tech Mahindra.

Among sectors, the PSU Bank index shed 2 percent, while Nifty Bank, Energy and Pharma indices down 1 percent each. However, Auto index added over 2 percent. The BSE midcap index was down 0.22 percent, while the smallcap index ended with marginal gains.

--------------------------------------------------------------------------------------------

Topic :- Time:3.00 PM

Nifty spot if manages to close above 18000 level then expect some sharp rise in the market in coming sessions and if it closes below above mentioned level then some decline can be seen. Avoid open short sell positions for tomorrow.

--------------------------------------------------------------------------------------------

Topic :- Time:2.50 PM

Just In:

China overtakes US in wealth gain over last two decade.

--------------------------------------------------------------------------------------------

Topic :- Time:2.30 PM

NATURALGAS Trading View:

NG is trading at 380.If it manages to hold above 377 level then expect it to rise till 384-385 levels quite soon and if it breaks and trade below 377 level then some decline can be seen in it. Buy from every decline is recommended in NG for today.

--------------------------------------------------------------------------------------------

Topic :- Time:2.00 PM

Nifty is still range bound.Nifty spot if manages to trade and sustain above 18080 level then expect some upmove and if it breaks and trade below 18040 level which is acting as immediate support then some decline can follow in it.

--------------------------------------------------------------------------------------------

Topic :- Time:1.30 PM

CRUDEOIL Trading View:

CRUDEOIL is trading at 6064.If it manages to trade and sustain above 6080 level then expect some upmove and if it breaks and trade below 6040 level then some decline can happen in it.

--------------------------------------------------------------------------------------------

Topic :- Time:1.00 PM

Nifty is still trading with minor losses however it is likely to show good upmove and set the right roads for PAYTM shares listing on 18 Nov. 

Nifty spot if manages to trade and sustain above 18100 level then expect some quick upmove in it and if it breaks and trade below 18060 level then some decline can follow in the market. 

--------------------------------------------------------------------------------------------

Topic :- Time:1.00 PM

Just In:

ED arrests Lalit Goyal, chairman of IREO Group in an alleged money laundering case.

--------------------------------------------------------------------------------------------

Topic :- Time:12.30 PM

COPPER Trading View:

COPPER is trading at 737.45.If it breaks and trade below 737 level then expect some further decline in it and if it manages to trade and sustain above 738.50 level then some upmove can be seen in it.

--------------------------------------------------------------------------------------------

Topic :- Time:12.00 PM

Nifty is showing some strength now. Nifty spot if manages to trade and sustain above 18100 level then expect some further upmove and if it breaks and trade below 18060 level then some decline can be seen in the market. Use all lows as an opportunity to go long in the market.

--------------------------------------------------------------------------------------------

Topic :- Time:11.30 AM

News Wrap Up:

1. Sensex at days low, down 300 pts; RIL falls 2%, SBI 1.5%

2. Indian Railways likely to reduce passenger fares by around 15%

3. Lenders to sell Videocon Oil Ventures, Amtek Auto debt to NARCL

4. Centres tax devolution to states doubled to Rs 95K cr in Nov: FM

5. Trade group to protest against e-com websites, alleges drug sale

6. Policybazaar surges 16% after strong debut, up 43% against issue price

7. Fundraising to conclude in current fiscal, says Vodafone Idea

8. NIIT surges 41% in one week on strong Q2 results

9. Auto shares in focus; Motherson Sumi, Varroc, Sharda Motor rally up to 10%

10. More middle-class Indians making big gains from bourses than before

--------------------------------------------------------------------------------------------

Topic :- Time:11.00 AM

After flat start nifty is now trading in red zone. Nifty spot if breaks and trade below 18000 level then expect some decline in it and if it manages to trade and sustain above 18040 level then some pull back can be seen in the market.

--------------------------------------------------------------------------------------------

Topic :- Nifty Opening Note

Indian Stock Market Trading View For Today:

Nifty is likely to turn volatile as the day progresses. Nifty spot if manages to trade and sustain above 18140 level then expect some upmove and if it breaks and trade below 18080 level then some decline can follow in the market. Please note this is just opening view and should not be considered as the view for the whole day.

--------------------------------------------------------------------------------------------

http://sharetipsinfo.comJust get registered at Sharetipsinfo and earn positive returns

Glenmark Pharmaceuticals has been included to the Dow Jones Sustainability Index in the emerging markets category for the fourth year in a row, according to the firm.

Glenmark Pharmaceuticals' stock dropped over 3% intraday to Rs 516.45 on November 16 after Morgan Stanley maintained a "underweight" rating on the stock with a target price of Rs 554.

The main business should expand in the low to mid-teens with consistent margins, but cash conversion and speciality monetisation are the key value drivers, according to the report.

Glenmark Pharmaceuticals been named to the Dow Jones Sustainability Index (DJSI) in the emerging markets category for the fourth year in a row, the business said on November 16.

Global investors, financial analysts, and other stakeholders see inclusion on this list as very prestigious, and it serves as a standard for investors that include sustainability considerations into their portfolios, according to the report.

Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, said, "Our inclusion in the coveted Dow Jones Sustainability Indices (DJSI) for the fourth consecutive year is a validation of our commitment to sustainability and reiterates our consistent performance across all sustainability indicators."

The addition of the DJSI underscores our dedication to uphold our sustainability strategy, which incorporates Environmental, Social, and Governance (ESG) principles to benefit our operations, stakeholders, communities, and the world as a whole."

On our live blog, you can follow all of the market action.

Other brokerages have the following to say about the stock and the company:

Lilladher Prabhudas

Glenmark Pharma has been able to sustain a high run-rate of EBITDA (earnings before interest, taxes, depreciation, and amortisation). Debt will continue to decline in FY23, owing to flat research and development costs and low capex requirements. While an increase in sales in the United States would be critical for earnings growth.

Over FY21-24E, we've assumed a 12 percent compound annual growth rate (CAGR) in EPS.

Any prospective out-licensing arrangements at Ichnos' (R&D arm) will be critical in the short term for any further meaningful debt reduction. With a target price of Rs 600 per share and a 15x FY23E P/E ratio, we recommend "accumulate."

Motilal Oswal Motilal Oswal Motilal Oswal

We cut our EPS forecasts for FY22 and FY23 by 4% each, owing to a) reduced momentum in the US generics market due to product-specific difficulties, b) continued pricing pressure on the existing portfolio, c) higher raw material costs, and d) higher logistic expenses.

Over FY21–23E, we predict an 11 percent profitability CAGR, driven by a 3%/5%/11% sales CAGR in the US/DF/Europe segment.

We estimate return ratios to remain in the mid-teens as EBITDA margins remain constant. On a limited upside from present levels, we remain "neutral."

The management expects sales growth of 10-15% in FY22 and a margin of roughly 19%. Over FY21-23E, a 13 percent PAT CAGR would be aided by a healthy India and US outlook, as well as debt reduction. Maintain a "buy" rating with a target price of Rs 625 based on a 15x FY23 P/E ratio.

Glenmark Pharma was trading at Rs 518.50 on the BSE at 10:08 a.m., down Rs 17.25, or 3.22 percent.